54548
Novid-20
Sugar-free lozenges on basis of antiviral cinnamon extract
Israel
Market: Food industry
Stage of the project: Prototype or product is ready
Date of last change: 07.11.2021
Israel
Market: Food industry
Stage of the project: Prototype or product is ready
Date of last change: 07.11.2021
Idea
Unique polyphenol extract of cinnamon (PE) inhibits viral activity for the broad spectrum of enveloped viruses. Novid 20 has developed an innovative industrial process for extraction of PE and production of PE-enriched sugar-free, tasty lozenges. In addition anti-herpes gel has been developed.
Current Status
Novid -20 has developed an innovative industrial process for extraction of a unique polyphenol compound of cinnamon, characterized by broad antiviral properties, branded Cinnovir (Product 2). At the next step, manufacturing of sugar-free, Cinnovir - enriched tasty lozenges (Product 1) has been launched. Lozenges are ready for sale as a food supplement for the COVID battlefield Additional product – An anti-herpes gel is undergoing a lab study.
Products 1,2
• Novid -20 is an active member of the CCC – The International Contagious Disease Control Consortium, operating as hub of Covid related solutions. CCC is engaged in search of marketing and strategic partners and investors. It has connections with governmental bodies in the US. Member companies are from the US, India, Latin America, Israel and Russia.
• Small-scale individual sales in Switzerland
• Strategic partner in Brazil is willing and capable of organizing marketing and human clinical study in the reputed hospital in Sao Paulo. However, the partner expects external funding of the study.
• Potential collaboration with a highly experienced professional in on-line marketing, former senior employee of Amazon, business angel
Product 3:
Marketing and co-developing partner in Israel for the anti-Herpes gel. The partner has developed the formulation and will supervise the clinical study in an Israeli hospital. Preliminary lab study is presently underway.
Products 1,2
• Novid -20 is an active member of the CCC – The International Contagious Disease Control Consortium, operating as hub of Covid related solutions. CCC is engaged in search of marketing and strategic partners and investors. It has connections with governmental bodies in the US. Member companies are from the US, India, Latin America, Israel and Russia.
• Small-scale individual sales in Switzerland
• Strategic partner in Brazil is willing and capable of organizing marketing and human clinical study in the reputed hospital in Sao Paulo. However, the partner expects external funding of the study.
• Potential collaboration with a highly experienced professional in on-line marketing, former senior employee of Amazon, business angel
Product 3:
Marketing and co-developing partner in Israel for the anti-Herpes gel. The partner has developed the formulation and will supervise the clinical study in an Israeli hospital. Preliminary lab study is presently underway.
Market
Overall Ingredients market estimate
Nutraceutical ingredients market as a whole is estimated to be valued at USD 162b in 2020. The immune health supplement market was USD 16.32 billion in 2019 and was projected to grow at a CAGR of 7.1% (www.fortunebusinessinsights.com) before the Covid outburst, which rocketed sales.
Market Segments for Covid related products
Hypothetical customers constitute the following sectors:
• The 5% of the non protected individuals (the vaccines are not 100% effective)
• Individuals who are allergic and/or immunocompromised
• Overexposed individuals like medical teams, who need an extra level of protection
• Individuals who are in confined places like air passengers
• Population of the Third World countries, where vaccination is difficult due to the need to keep the vaccine in refrigeration
For the sake of simplicity, we will consider only one segment: the individuals refusing to be vaccinated.
Statistical assessment of their numbers vary considerably, in some countries they are rumored to constitute as many as 1/3 of the entire population. We will conservatively assume them to constitute 10% of the population of the developed countries and of the middle classes of China, India and Brazil. Thus, we arrive at approximately 120m individuals. Assuming market penetration of 5%, and annual consumption of as low as $100 per person we arrive at annual sales of $600m.
Market for Herpes related products
Herpes is exceedingly common in the developing countries encompassing hundreds of millions of individuals. "Taken together, an estimated 596.0 million–655.7 million people, 16.0–17.6% of the world’s population 15–49 years of age, had genital HSV type 1 or HSV type 2 or both…"
https://www.who.int/news/item/01-05-2020-massive-proportion-world-population-living-with-herpes-infection
Our brand new anti-Herpes topical gel will target only HSV1 – over 600m individuals.
Nutraceutical ingredients market as a whole is estimated to be valued at USD 162b in 2020. The immune health supplement market was USD 16.32 billion in 2019 and was projected to grow at a CAGR of 7.1% (www.fortunebusinessinsights.com) before the Covid outburst, which rocketed sales.
Market Segments for Covid related products
Hypothetical customers constitute the following sectors:
• The 5% of the non protected individuals (the vaccines are not 100% effective)
• Individuals who are allergic and/or immunocompromised
• Overexposed individuals like medical teams, who need an extra level of protection
• Individuals who are in confined places like air passengers
• Population of the Third World countries, where vaccination is difficult due to the need to keep the vaccine in refrigeration
For the sake of simplicity, we will consider only one segment: the individuals refusing to be vaccinated.
Statistical assessment of their numbers vary considerably, in some countries they are rumored to constitute as many as 1/3 of the entire population. We will conservatively assume them to constitute 10% of the population of the developed countries and of the middle classes of China, India and Brazil. Thus, we arrive at approximately 120m individuals. Assuming market penetration of 5%, and annual consumption of as low as $100 per person we arrive at annual sales of $600m.
Market for Herpes related products
Herpes is exceedingly common in the developing countries encompassing hundreds of millions of individuals. "Taken together, an estimated 596.0 million–655.7 million people, 16.0–17.6% of the world’s population 15–49 years of age, had genital HSV type 1 or HSV type 2 or both…"
https://www.who.int/news/item/01-05-2020-massive-proportion-world-population-living-with-herpes-infection
Our brand new anti-Herpes topical gel will target only HSV1 – over 600m individuals.
Problem or Opportunity
Covid-19
Viral infections are widely spread and are highly contagious. Despite the impressive success of the nascent vaccines against Covid-19, there are limits of their applications:
• Vaccines do not ensure total protection. Thus, vaccines of Pfizer and Moderna against Covid-19 provide approximately 95% protection. This means that the remaining 5% are not protected.
• Viruses mutate frequently, challenging the vaccines' efficacy.
• There are vaccines against the flu, however many people still die from the flu.
https://www.health.com/condition/cold-flu-sinus/how-many-people-die-of-the-flu-every-year
https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
• Major population groups who do not agree to get vaccinated. (In case of Covid-19 vaccines, according to Gallup, a third of Americans currently say they have no interest in taking a vaccine. Due to this mistrust on one hand and the pressing needs on another hand, these population groups most probably will seek alternative solutions and embrace natural remedies.
https://www.reuters.com/article/health-coronavirus-vaccine-hesitancy/vaccine-hesitancy-may-undermine-fight-against-covid-19-uk-report-says-idUSL8N2HV7J8
There is an acute need for complementary efficacious wide-spectrum antiviral ingredients.
Herpes
No cure of Herpes is available, existing remedies are directed against symptoms, rather than against the root cause of the disease.
Viral infections are widely spread and are highly contagious. Despite the impressive success of the nascent vaccines against Covid-19, there are limits of their applications:
• Vaccines do not ensure total protection. Thus, vaccines of Pfizer and Moderna against Covid-19 provide approximately 95% protection. This means that the remaining 5% are not protected.
• Viruses mutate frequently, challenging the vaccines' efficacy.
• There are vaccines against the flu, however many people still die from the flu.
https://www.health.com/condition/cold-flu-sinus/how-many-people-die-of-the-flu-every-year
https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)
• Major population groups who do not agree to get vaccinated. (In case of Covid-19 vaccines, according to Gallup, a third of Americans currently say they have no interest in taking a vaccine. Due to this mistrust on one hand and the pressing needs on another hand, these population groups most probably will seek alternative solutions and embrace natural remedies.
https://www.reuters.com/article/health-coronavirus-vaccine-hesitancy/vaccine-hesitancy-may-undermine-fight-against-covid-19-uk-report-says-idUSL8N2HV7J8
There is an acute need for complementary efficacious wide-spectrum antiviral ingredients.
Herpes
No cure of Herpes is available, existing remedies are directed against symptoms, rather than against the root cause of the disease.
Solution (product or service)
Provide the details about the product and the services …. And how it can help to resolve problems the client may have. (Add the photo of the product and the end of the questioner)
It has been discovered that Cinnovir immediately inhibits viral activity by adhering to the viral envelope or spikes and, hence, can potentially assist in prevention/treatment of a large variety of enveloped viruses including the COVID-19. Following this discovery, an innovative industrial process for extraction of Cinnovir and production of Cinnovir-enriched sugar-free, tasty lozenges (candies) has been developed.
1. Product 1 Cinnovir Lozenges for consumption as a food supplement, containing 40mg of Cinnovir each
2. Product 2 (R&D) Cinnovir Nasal Spray
3. Product 3 (R&D) anti-Herpes Cinnovir Topical Spray
It has been discovered that Cinnovir immediately inhibits viral activity by adhering to the viral envelope or spikes and, hence, can potentially assist in prevention/treatment of a large variety of enveloped viruses including the COVID-19. Following this discovery, an innovative industrial process for extraction of Cinnovir and production of Cinnovir-enriched sugar-free, tasty lozenges (candies) has been developed.
1. Product 1 Cinnovir Lozenges for consumption as a food supplement, containing 40mg of Cinnovir each
2. Product 2 (R&D) Cinnovir Nasal Spray
3. Product 3 (R&D) anti-Herpes Cinnovir Topical Spray
Competitors
Most supplements are minerals like zinc or vitamins. In addition, there are dietary supplements that contain production products (usually extracts) from botanical sources. Our product is based on a hitherto unknown cinnamon ingredient that has considerable antiviral ability. The market is looking forward to innovation and especially in the field of supplements from a botanical source. The closest product to us in this market is nutritional supplements derived from blueberry extract
https://www.amazon.com/Elderberry-Herbal-Supplements/b?ie=UTF8&node=3765511
Black elderberry-based supplements are rich in bioflavonoids and are sold in the market as dietary supplements without making medical claims. These supplements are recommended for use against the flu. The antiviral activity of black elderberry is different from the activity of our product and in any case is not prescribed as a remedy or protection against COVID virus.
In reality, black elderberry supplements are not a direct competitor of Cinnovir and are mentioned only as an example of supplements to strengthen the immune system available in the marketplace.
Due to the complexity of the biological processes, there exists no single "miracle" drug or preventative methods that are supposed to resolve any major medical problem. Therefore, there is a proliferation of vaccines and drugs and protective methods offered against the coronavirus.
From this point of view, Cinnovir should be regarded as complementary to both vaccines and passive defenses such as masks, antiseptics and the like. Although it is now fashionable to present any development as "disruptive", complementary technologies are no less valuable.
Example: Sambucus Elderberry
Bio Schwartz
https://bioschwartz.com/collections/immune-support/products/sambucus-elderberry-capsules
https://www.amazon.com/Elderberry-Herbal-Supplements/b?ie=UTF8&node=3765511
Black elderberry-based supplements are rich in bioflavonoids and are sold in the market as dietary supplements without making medical claims. These supplements are recommended for use against the flu. The antiviral activity of black elderberry is different from the activity of our product and in any case is not prescribed as a remedy or protection against COVID virus.
In reality, black elderberry supplements are not a direct competitor of Cinnovir and are mentioned only as an example of supplements to strengthen the immune system available in the marketplace.
Due to the complexity of the biological processes, there exists no single "miracle" drug or preventative methods that are supposed to resolve any major medical problem. Therefore, there is a proliferation of vaccines and drugs and protective methods offered against the coronavirus.
From this point of view, Cinnovir should be regarded as complementary to both vaccines and passive defenses such as masks, antiseptics and the like. Although it is now fashionable to present any development as "disruptive", complementary technologies are no less valuable.
Example: Sambucus Elderberry
Bio Schwartz
https://bioschwartz.com/collections/immune-support/products/sambucus-elderberry-capsules
Advantages or differentiators
Comparative Advantages of Cinnovir
• It is an inexpensive, non-toxic and naturally derived product, which provides an additional protective layer against COVID-19 infection as well as flu and other viral infections.
• Appropriate for everyone who for whatever reason is not vaccinated like allergic people
• Appropriate for those (5% or more) cases where vaccination is not effective
• Appropriate for over-exposed individuals like medical personnel
• Appropriate for children
• Appropriate for the wide "vaccine-hesitant" population who mistrust the nascent vaccines
• Unlike the nascent vaccines Cinnovir does not need refrigeration, hence is appropriate for Third World countries.
• It is an inexpensive, non-toxic and naturally derived product, which provides an additional protective layer against COVID-19 infection as well as flu and other viral infections.
• Appropriate for everyone who for whatever reason is not vaccinated like allergic people
• Appropriate for those (5% or more) cases where vaccination is not effective
• Appropriate for over-exposed individuals like medical personnel
• Appropriate for children
• Appropriate for the wide "vaccine-hesitant" population who mistrust the nascent vaccines
• Unlike the nascent vaccines Cinnovir does not need refrigeration, hence is appropriate for Third World countries.
Finance
Revenue streams
#1 Sales of Cinnovir Lozenges (Product 1), manufactured in Israel
#2 Sales of Cinnovir 10% Concentration (Product 2), manufactured in Israel
#3 Sales of anti-Herpes topical gel (Product 3), manufactured in Israel
#4 Outsourced manufacturing
Cost structure
Cinnovir 10% Concentration for Functional Food Manufacturers and Antiviral Sprays
• Production cost $30/kg
• Wholesale cost $55/kg
Cinnovir Lozenges (in bulk)
• Production cost $14/kg
• Wholesale cost $25/kg
Cinnovir Lozenges (in pack of 40 lozenges)
• Production cost $3.4/pack
• Wholesale cost $6.2/pack
Manufacturing is outsourced
• Royalties 10%
Projected Metrics
According to our financial Model:
Break-even point within 1 year
ROI within 1 year
Total money In /month (month 36th) $2.5m
Total money Out / months (month 36th) $0.6m
Sales/month (month 50th) $4m
#1 Sales of Cinnovir Lozenges (Product 1), manufactured in Israel
#2 Sales of Cinnovir 10% Concentration (Product 2), manufactured in Israel
#3 Sales of anti-Herpes topical gel (Product 3), manufactured in Israel
#4 Outsourced manufacturing
Cost structure
Cinnovir 10% Concentration for Functional Food Manufacturers and Antiviral Sprays
• Production cost $30/kg
• Wholesale cost $55/kg
Cinnovir Lozenges (in bulk)
• Production cost $14/kg
• Wholesale cost $25/kg
Cinnovir Lozenges (in pack of 40 lozenges)
• Production cost $3.4/pack
• Wholesale cost $6.2/pack
Manufacturing is outsourced
• Royalties 10%
Projected Metrics
According to our financial Model:
Break-even point within 1 year
ROI within 1 year
Total money In /month (month 36th) $2.5m
Total money Out / months (month 36th) $0.6m
Sales/month (month 50th) $4m
Business model
Regional marketing and distribution companies (RMC) will get marketing rights for the corresponding region and they shall carry out marketing of the products, resolve regulatory issues and if necessary organize Clinical studies.
Novid will organize manufacturing in Israel and will supply the RMC with the ready products. In the event that the demand exceeds the manufacturing capabilities in Israel, then manufacturing (all or partly) will be transferred to the regional manufacturers in exchange for the royalties.
Novid will be in charge of new and upgraded products and IP protection in the regions where sales are taking place.
Channels
• Wholesale distributors of food supplements
• Assistance by strategic advisors
• On-line sales via Amazon, Alibaba, eBay
• The businesses affected by the Corona; for example: nursery homes
• "Word-of-mouth marketing",
• PR, sharing the clinical results via social networks
Projected Metrics
According to our financial Model:
Break-even point within 1 year
ROI within 1 year
Total money In /month (month 36th) $2.5m
Total money Out / months (month 36th) $0.6m
Sales/month (month 50th) $4m
Novid will organize manufacturing in Israel and will supply the RMC with the ready products. In the event that the demand exceeds the manufacturing capabilities in Israel, then manufacturing (all or partly) will be transferred to the regional manufacturers in exchange for the royalties.
Novid will be in charge of new and upgraded products and IP protection in the regions where sales are taking place.
Channels
• Wholesale distributors of food supplements
• Assistance by strategic advisors
• On-line sales via Amazon, Alibaba, eBay
• The businesses affected by the Corona; for example: nursery homes
• "Word-of-mouth marketing",
• PR, sharing the clinical results via social networks
Projected Metrics
According to our financial Model:
Break-even point within 1 year
ROI within 1 year
Total money In /month (month 36th) $2.5m
Total money Out / months (month 36th) $0.6m
Sales/month (month 50th) $4m
Money will be spent on
• Replacement of the UF membranes used for the Cinnovir extraction in order to improve the yield of the system
• IP Protection
• Small-scale human study
• IP Protection
• Small-scale human study
Offer for investor
To be negotiated
Team or Management
Risks
Cinnamon is widely used and is considered safe. Therefore, there is no risk related to its safety. However,
1. Cinnovir has been tested only in pre-clinical studies. Efficacy was not yet proven in human clinical study
2. Sales projections may not materialize, since the sales volumes significantly depend on the possibility to claim health benefits. This can be done by citing the outcome of the human studies. So far, no statistically significant human studies have been made.
3. Another potential potential risk factor – potential shrinking of the vaccine sceptics' population group
1. Cinnovir has been tested only in pre-clinical studies. Efficacy was not yet proven in human clinical study
2. Sales projections may not materialize, since the sales volumes significantly depend on the possibility to claim health benefits. This can be done by citing the outcome of the human studies. So far, no statistically significant human studies have been made.
3. Another potential potential risk factor – potential shrinking of the vaccine sceptics' population group
Incubation/Acceleration programs accomplishment
No
Won the competition and other awards
Not yet
Invention/Patent
Cinnovir production technology as well as the compound are proprietary and patent pending (IL277753& IL283292, PCT/IL2021/051186). Preparation of an additional patent related to the anti-Herpes application is under way.
Photos
Presentation
Sign in/Sign up